CAPMATINIB for Lung adenocarcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 39 adverse event reports in the FDA FAERS database where CAPMATINIB was used for Lung adenocarcinoma.
Most Reported Side Effects for CAPMATINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 411 | 17.9% | 410 | 23 |
| Peripheral swelling | 283 | 12.3% | 10 | 34 |
| Fatigue | 257 | 11.2% | 16 | 40 |
| Oedema peripheral | 247 | 10.7% | 25 | 43 |
| Nausea | 240 | 10.4% | 28 | 56 |
| Malignant neoplasm progression | 178 | 7.7% | 79 | 42 |
| Dyspnoea | 141 | 6.1% | 24 | 51 |
| Oedema | 130 | 5.7% | 12 | 17 |
| Asthenia | 113 | 4.9% | 15 | 30 |
| Non-small cell lung cancer | 96 | 4.2% | 37 | 21 |
| Decreased appetite | 95 | 4.1% | 16 | 30 |
| Joint swelling | 92 | 4.0% | 1 | 8 |
| Vomiting | 83 | 3.6% | 11 | 22 |
| Dysphagia | 80 | 3.5% | 11 | 5 |
| Product dose omission issue | 76 | 3.3% | 5 | 15 |
Other Indications for CAPMATINIB
Product used for unknown indication (838)
Non-small cell lung cancer (543)
Lung neoplasm malignant (420)
Non-small cell lung cancer metastatic (104)
Lung carcinoma cell type unspecified stage 0 (58)
Non-small cell lung cancer stage iv (31)
Neoplasm malignant (22)
Lung cancer metastatic (20)
Non-small cell lung cancer recurrent (12)
Lung adenocarcinoma stage iv (11)
Other Drugs Used for Lung adenocarcinoma
PEMETREXED (4,280)
PEMBROLIZUMAB (3,954)
CARBOPLATIN (3,888)
BEVACIZUMAB (1,522)
PACLITAXEL (1,216)
NIVOLUMAB (1,162)
ATEZOLIZUMAB (1,032)
CISPLATIN (1,003)
DOCETAXEL (977)
OSIMERTINIB (936)